Ibogaine opioid treatment research has moved significantly forward in 2025 and 2026, with new clinical data, a landmark $50 million Texas state investment, and a federal executive order directing agencies to accelerate review. The evidence shows real potential for...
Executive burnout psychedelic therapy is moving from the research margins into serious clinical conversation. A growing body of peer-reviewed evidence suggests that psilocybin-assisted therapy can reduce burnout and depressive symptoms more durably than conventional...
Research on psilocybin alcohol use disorder treatment, including a landmark 2022 randomized controlled trial published in JAMA Psychiatry, has shown meaningful reductions in heavy drinking days compared to placebo. The findings are significant, but the research is...
Psychedelic therapy for executives is moving beyond reputation and into clinical evidence. A growing number of C-suite leaders are using professionally supported psilocybin and ketamine experiences to address burnout, decision fatigue, and stalled thinking. Here is...
